Literature DB >> 25115843

Validation of an extended French version of ID Migraine™ as a migraine-screening tool.

Sylvie Streel1, Anne-Françoise Donneau2, Nadia Dardenne2, Axelle Hoge2, Olivier Bruyère2, Adelin Albert2, Michèle Guillaume2, Jean Schoenen3.   

Abstract

INTRODUCTION: Migraine has a considerable social, economic, physical and emotional burden but remains underdiagnosed and undertreated. A specific migraine screening tool could help remove barriers to health care and be an attractive instrument for epidemiological studies. The objective of this work was to assess the validity of an extended French version of ID Migraine™ as a migraine-screening tool.
METHODS: Sixty-seven subjects from the NESCaV study (2010-2012) completed the migraine screen and were diagnosed by a neurologist specializing in headache medicine using the International Classification of Headache Disorders, 2nd edition criteria (gold standard). Agreement between the two diagnoses was evaluated by Cohen kappa coefficient (κ). Sensitivity, specificity and predictive values of the migraine screen were calculated.
RESULTS: Migraine was diagnosed in 21 (31.3%) of the 67 subjects according to the screening tool and in 24 (35.8%) by the neurologist (κ = 0.90). The prevalence of migraine was unrelated to age, gender, education and perception of financial resources. Sensitivity and specificity of the screen were 87.5% and 100%, respectively. The screen prevalence of migraine with aura was 10.4% (sensitivity and specificity: 83.3% and 96.7%, respectively).
CONCLUSION: The extended French version of ID Migraine™ (ef-ID Migraine) is a validated tool to screen migraine in French-speaking countries. © International Headache Society 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Migraine; screening tool; sensitivity; specificity; validity

Mesh:

Year:  2014        PMID: 25115843     DOI: 10.1177/0333102414544910

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  4 in total

1.  Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).

Authors:  Simona Sacco; Gabriele S Merki-Feld; Karen Lehrmann Ægidius; Johannes Bitzer; Marianne Canonico; Tobias Kurth; Christian Lampl; Øjvind Lidegaard; E Anne MacGregor; Antoinette MaassenVanDenBrink; Dimos-Dimitrios Mitsikostas; Rossella Elena Nappi; George Ntaios; Per Morten Sandset; Paolo Martelletti
Journal:  J Headache Pain       Date:  2017-10-30       Impact factor: 7.277

2.  Lifting the burden of headache in China: managing migraine in a SMART way.

Authors:  Shengyuan Yu; Timothy J Steiner
Journal:  J Headache Pain       Date:  2017-08-08       Impact factor: 7.277

Review 3.  The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review.

Authors:  Emanuel Schembri; Michelle Barrow; Christopher McKenzie; Andrew Dawson
Journal:  Korean J Pain       Date:  2022-01-01

4.  Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine.

Authors:  Delphine Magis; Kevin D'Ostilio; Aurore Thibaut; Victor De Pasqua; Pascale Gerard; Roland Hustinx; Steven Laureys; Jean Schoenen
Journal:  Cephalalgia       Date:  2016-06-23       Impact factor: 6.292

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.